Generic Name: encorafenib
Brand Name: Braftovi
Manufacturer: Pfizer Canada ULC
Therapeutic Area: Metastatic colorectal cancer
Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.
Manufacturer Requested Reimbursement Criteria1: In combination with cetuximab or panitumumab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAFV600E mutation, after prior therapy.
Submission Type: Initial
Tumour Type: Gastrointestinal
Project Status: Pending
Call for patient/clinician input open: November 17, 2020
Call for patient/clinician input closed: January 15, 2021
Anticipated Date: December 15, 2020
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.